Nitazenes.
A hidden supply.
A local emergency.

Scotland’s experience exposes the danger of treating a falling UK death count as reassurance. Police leaders need a response that detects dangerous changes in their own drug supply and reaches people before the next overdose.

The National Crime Agency recorded 435 nitazene-related deaths across the UK in 2024 and 359 in 2025, with further test results expected to increase the latter figure. Within that national decline, it reported an increase in Scotland. NCA, National Strategic Assessment 2026.

The question is what police leaders should take from that difference. The evidence supports local drug monitoring, rapid emergency response and accessible treatment. It does not support assuming that a national average describes the risk in every community.

Updated 20 September 2026: this revision adds the BBC’s Scottish reporting, makes the national and Scottish distinction explicit, and separates English preparedness guidance from Scottish arrangements.

Scotland changes the reading of the national total

James Cook’s BBC report, 20 September 2026, describes a rapidly changing synthetic-drug supply. It reports investigations into suspected laboratories in Patna, Ayrshire, in July 2025 and Loanhead, Midlothian, in February 2026. Five arrests across the two investigations are reported. These remain descriptions of suspected laboratories, not findings of guilt.

The report also describes plans for an expanded national drug-testing role at Dundee University’s Leverhulme Research Centre for Forensic Science. Faster information could help services respond, but the report is not an evaluation showing that the expansion has reduced deaths.

Its reference to an expected rise in forthcoming annual drug-death figures must also remain an expectation. This article does not treat an unreleased result as an established statistic. BBC report, syndicated copy.

There are two separate measurement problems. A UK total can conceal opposite movements between its constituent countries. A total still awaiting laboratory results can also change after publication. Neither makes the data useless. Both change the conclusions it can carry.

For a local commander, the practical implication is to ask what is happening locally and how quickly the information arrives. A fall elsewhere does not answer that question.

The substance people buy may not be the substance they take

Nitazenes are a group of synthetic opioids. Many are highly toxic in small quantities; treating every compound as having one fixed potency would be misleading. Government guidance identifies several different nitazenes and warns about their overdose risk. OHID, guidance on potent synthetic opioids.

The NCA describes broadly stable UK heroin supply in 2025 alongside continuing risks from the addition of synthetic opioids to heroin and illicit medicines. That supports a concern about hidden contents without establishing that heroin has been replaced nationwide. NCA, 2026.

This changes what useful information at an overdose scene looks like. Officers should record what the person or witnesses believed the substance was, while keeping that account separate from any later analytical result. The apparent drug name is information to investigate, not a laboratory finding.

It also changes the intended audience for warnings. Communications aimed only at people who identify themselves as heroin users risk failing to reach people buying tablets. The warning should explain the verified local concern in language people recognise, state what remains unknown and give an immediate action.

A negative test strip must not become a safety certificate. OHID warns that strips can miss substances, may not detect every variant and do not establish how much of a drug is present. OHID, drug-testing limitations.

Naloxone needs to be available where overdoses happen

Naloxone reverses opioid overdose, including overdose involving potent synthetic opioids. Government guidance advises repeated standard dosing until breathing is restored while an ambulance is on its way. OHID, naloxone guidance.

For officers, this is an operational readiness question. Training, accessible stock and a replacement route need to work together. A kit stored somewhere an attending officer cannot reach offers little reassurance. The proposed test is whether the people expected to respond can demonstrate the response with the equipment they would actually use.

Naloxone provision should also reach people outside treatment. The same guidance identifies outreach, pharmacies and services for homeless people as potential distribution routes, alongside improving treatment access and retention. OHID, local response guidance.

This is where an enforcement-only account becomes inadequate. Removing a dangerous supply can be a policing objective; responding to the person already exposed needs an immediate health intervention. Longer-term treatment has a separate role. These tasks need a joint plan rather than competing claims about which profession owns the problem.

England’s plan cannot simply be relabelled for Scotland

The Home Office’s June 2025 preparedness review applies to England. It draws on local partnership plans and a tabletop exercise, rather than an experimental evaluation proving a particular reduction in mortality. Its recommendations cover out-of-hours arrangements, exercises, naloxone availability, information sharing and forensic testing. Home Office, Local preparedness for synthetic opioids in England.

Scotland has a separate Public Health Scotland Rapid Action Drug Alerts and Response (RADAR) nitazenes alert. Scottish readers should use that national alert alongside their own local arrangements. England’s partnership and coroner terminology should not be carried across as though the institutions were interchangeable.

The common operational requirement is a route from an unusual event to an accountable decision. The following diagram is a proposed way to test that route, not a description of a mandatory national procedure.

Test the gap between a plan and a response

Chief officers and health partners should run a short exercise using an uncertain overdose cluster, including a report received outside office hours. The English review provides a basis for rehearsing arrangements; the checks below are proposed measures of whether the local process works.

These are process measures. Passing an exercise would show that a route works under test conditions; it would not prove that the intervention prevents deaths. A later review should examine actual response delays, non-fatal overdoses and fatalities together, recognising that better detection can itself increase the recorded numbers.

There are costs and competing demands. Laboratory capacity, staff availability and outreach cannot be assumed. Repeated poorly targeted alerts can also make communication less useful. Local leaders should therefore agree who decides to issue a warning, what evidence is sufficient for an interim response and when the warning will be updated or withdrawn.

The wider treatment argument is developed in Drug policy: where the evidence is strong, and where it is not. For this article, the decision is more immediate: make the local response testable. A chief officer should be able to establish who will act on tonight’s warning and what resources that person can actually mobilise.